Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB 111077 in Subjects with Advanced Hepatocellular Carcinoma (HCC)

Trial Profile

A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB 111077 in Subjects with Advanced Hepatocellular Carcinoma (HCC)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs OPB 111077 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Korea Otsuka Pharmaceutical
  • Most Recent Events

    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 07 May 2017 Status changed from recruiting to discontinued.
    • 28 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top